PROTACs are heterobifunctional small molecules composed of three modular elements: a warhead ligand that binds the protein of interest (POI), a linker of variable length and chemistry, and a recruiter ligand that engages an E3 ubiquitin ligase. Upon simultaneous binding of both the POI and E3 ligase, a ternary complex forms, leading to ubiquitination of the POI and its subsequent degradation by the 26S proteasome. Crucially, the PROTAC molecule is released after each degradation cycle, enabling sub-stoichiometric catalytic activity — a fundamental advantage over occupancy-driven inhibitors.

This dataset encompasses literature from 2018–2025 and active patents from CN, US, and IN jurisdictions. The technology encompasses classical small-molecule PROTACs using CRBN and VHL E3 ligases, next-generation non-small-molecule PROTACs incorporating peptides, nucleic acid aptamers, and antibodies, stimulus-responsive and spatioselective degraders, computational and AI-assisted PROTAC design platforms, and extension to extracellular, membrane-bound, and even bacterial protein targets. Learn more about PatSnap’s life sciences intelligence platform.

The field has matured rapidly: the PROTAC-DB database catalogued 1,662 PROTACs, 202 warheads, 65 E3 ligands, and 806 linkers as of 2020 — reflecting the rapid combinatorial expansion of chemical space. The first small-molecule PROTACs entered clinical trials in 2019, with clinical proof-of-concept for ARV-110 and ARV-471 in cancer reported in 2020. The World Intellectual Property Organization (WIPO) has tracked accelerating patent filings in targeted protein degradation since 2019.

AI and Computational De Novo PROTAC Design: The most recent US patent in the dataset (Ainnocence Technologies LLC, 2026) and tools such as PROTACable (2023) and PRODE (2023) signal a shift toward automated, AI-accelerated PROTAC molecule generation — integrating 3D ternary complex modeling, equivariant neural networks, and free-energy calculations. This addresses the historically empirical and low-throughput nature of PROTAC optimization. PatSnap’s IP analytics platform enables teams to track these computational design patents in real time.

DEL-PROTAC Integration: WuXi AppTec’s 2024–2025 CN patents describe the integration of DNA-encoded library (DEL) technology with PROTAC molecular design — enabling high-throughput identification of novel warheads and linker chemistries, while combining ternary complex conformation prediction with DEL screening.

Tumor-Responsive In-Situ PROTAC Generation: Zhejiang University of Technology’s 2024 CN patent describes building-block precursors that generate PROTAC molecules in situ within the tumor microenvironment — a click-chemistry-inspired approach to achieve conditional, tumor-localized protein degradation.

Antibody-PROTAC Conjugates: The PROxAb Shuttle platform (2023) demonstrates non-covalent plug-and-play VHH-based antibody-PROTAC complexes for tumor-targeted delivery, overcoming oral bioavailability and cell-type specificity challenges. The National Institutes of Health (NIH) has funded research in targeted protein degradation delivery systems. See how PatSnap customers use these insights for competitive intelligence.

Biologic and mRNA-Encoded PROTACs (RiboPROTACs): The encoding of PROTAC protein degraders in circular mRNA (cmRNA) for intracellular delivery was demonstrated in 2022, enabling degradation of nuclear proteins such as PCNA that are inaccessible to small-molecule formats. The European Patent Office has noted increasing filings in mRNA-based therapeutic delivery platforms.

Peptide-Based PROTAC Condensates: The National Center for Nanoscience and Technology’s 2025 CN patent describes dynamically adaptive peptide-based PROTAC condensates that simultaneously target HER2, EGFR, and RAS via supramolecular self-assembly — enabling multi-target depletion from a single entity. Access PatSnap’s chemistry intelligence tools to track emerging formulation patents.